Moghetti, P <br/><br/>
Spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist.  [electronic resource] 

 -  The Journal of clinical endocrinology and metabolism  Apr 1999 
 - 1250-4 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0021-972X 
<br/><br/><label>Standard No.: </label>10.1210/jcem.84.4.5606  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Bone Density--drug effects<br/>Bone Resorption--prevention & control<br/>Bone and Bones--drug effects<br/>Female<br/>Flutamide--therapeutic use<br/>Hirsutism--drug therapy<br/>Humans<br/>Polycystic Ovary Syndrome--drug therapy<br/>Spironolactone--therapeutic use<br/>Triptorelin Pamoate--adverse effects